• 1
    Obermair A, Handisurya A, Kaider A, Sevelda P, Kolbl H, Gitsch G. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients. Cancer 1998; 83: 72631.
  • 2
    Tesarova P, Kvasnicka J. Erythropoietin therapy in cancer patients. Cas Leuk Ces 1995; 20: 64750.
  • 3
    DeRienzo DP, Saleem A. Anaemia of chronic disease: a review of pathogenesis. Texas Med 1990; 86: 803.
  • 4
    Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998; 25(Suppl 7): 26.
  • 5
    Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A(Suppl 2): S28.
  • 6
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alpha on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15(3): 121834.
  • 7
    Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16: 341225.
  • 8
    Gabrilove JL, Einhorn LH, Livinston RB, Winer E, Cleeland CS. Once-weekly dosing of epoetin alpha is similar to three times weekly dosing in increasing hemoglobin and quality of life. Proc Am Soc Clin Oncol 1999; 18: 574A.
  • 9
    Manegold C. The causes and prognostic significance of low hemoglobin levels in tumor patients. Strahlenther Onkol 1998; 174(Suppl IV): 179.
  • 10
    Ludwig H, Fritz E. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment. Semin Oncol 1998; 25(Suppl 7): 358.
  • 11
    Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993; 2: 12145.
  • 12
    Kleinbaum DG, Kupper LL, Morgenstern H. Point estimation of overall effect and interval estimation of effect. In: KleinbaumDG, KupperLL, MorgensternH, editors. Epidemiologic research. Principles and quantitative methods, 1st edition. New York: Van Nostrand Reinhold, 1982: 34076.
  • 13
    Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 1995; 48: 4557.
  • 14
    Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992; 327: 24854.
  • 15
    Takifuji N, Fukuoka M, Negoro S, Takada M, Kusonoki Y, Matsui K, et al. Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy. Gan To Kagaku Ryoho 1990; 17( 3 Pt 2): 42934.
  • 16
    Sekiguchi K, Yamashita T, Hayashi S, Aoki M, Kitahara T, Sekine H, et al. Prognostic factors of radiation therapy for patients with nonoperative Stage III non-small cell lung cancer. Nippon Igaku Hoshasen Gakkai Zasshi 1994; 54(10): 9991006.
  • 17
    Ding SL, Ger LP, Kao SJ, Shen CY. Small cell-lung cancer: survival analysis of 96 cases. Chung Hua I Hsueh Tsa Chih 1989; 43 (3): 197204.
  • 18
    Skladowski K, Zajusz A, Swiatnicka J, Maciejewska M, Krupska T, Majewski S, et al. Prognostic factors in radiotherapy of supraglottic cancer. Otolaryngol Pol 1996; 50(6): 57986.
  • 19
    Zakraoui L, Cheour I, Jeridi T, Jellouli N, Bergaoui N, Moalla M, et al. Prognostic factors in multiple myeloma. Critical analysis based on a multicenter study of 53 cases. Tunis Med 1988;66(10): 66372.
  • 20
    Grogan M, Thomas GM, Melamed I, Wong FLW, Pearcey RG, Joseph PK, et al. The importance of maintaining high hemoglobin levels during radiation treatment of carcinoma of the cervix. Cancer 1999; 86: 152836.
  • 21
    Sorensen JB, Badsberg JH, Olsen J. Prognostic factors in inoperable adenocarcinoma of the lung. Cancer Res 1989; 49: 574854.
  • 22
    Ohlhauser C, Bulzebruck H, Ebert W, Drings P, Wannenmacher M. Prognostic factors for survival in inoperable non-small-cell lung cancer. A multivariate regression analysis of 456 patients with radiation therapy. Oncology 1997;20: 12631.
  • 23
    Cohen MH, Makuch R, Johnston-Early A, Ihde DC, Bunn PA, Fossieck BE, et al. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 1981; 65: 18795.
  • 24
    Yamamoto N, Tamura T, Fukuoka M. Survival and prognostic factors in lung cancer patients treated in Phase I trials: Japanese experience. Int J Oncol 1999; 15: 73741.
  • 25
    Sorensen JB, Badsberg JH. Prognostic factors in resected Stages I and II adenocarcinoma of the lung. A multivariate regression analysis of 137 consecutive patients. J Thorac Cardiovasc Surg 1990;99(2): 218-26.
  • 26
    Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986; 46(8): 418994.
  • 27
    Tamura M, Ueoka H, Kiura K, Tabata M, Shibayama T, Miyatake K, et al. Prognostic factors of small-cell lung cancer in Okayama Lung Cancer Study Group trials. Acta Med Okayama 1998; 52(2): 10511.
  • 28
    Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG, Tobias JS. Prognostic significance of laboratory parameters measured at prognosis in small cell carcinoma of the lung. Cancer Res 1985; 45: 287882.
  • 29
    Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, et al. A prognostic factor risk index in advanced non small cell lung cancer treated with cisplatin containing combination chemotherapy. Cancer Chemother Pharmacol 1992; 30: 16.
  • 30
    Gail MH, Eagan RT, Feld R, Ginsberg R, Goodell B, Hill L, et al. Prognostic factors in patients with resected stage non-small cell lung cancer. Cancer 1984; 54: 180213.
  • 31
    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 161826.
  • 32
    Okamoto H, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, et al. Chemotherapy-induced anemia in patients with primary lung cancer. Ann Oncol 1992; 3(10): 81924.
  • 33
    Frommheld H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. Strahlenther Onkol 1998; 174(Suppl IV): 314.
  • 34
    Bryne M, Eide GE, Lilleng R, Langmark F, Thrane PS, Dabelsteen E. A multivariate analysis of the prognosis of oral squamous cell carcinoma. Cancer 1991; 68: 19948.
  • 35
    Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998; 42: 106975.
  • 36
    Dubray B, Mosseri V, Brunin F, Jaulerry C, Poncet P, Rodriguez J, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996; 201: 5538.
  • 37
    Fazekas JT, Scott C, Marcial V, Davis LW, Wasserman T, Cooper JS. The role of hemoglobin concentration in the outcome of misonidazole-sensitized radiotherapy of head and neck cancers: based on RTOG trial 79-15. Int J Radiat Oncol Biol Phys 1989; 17(6): 117781.
  • 38
    Canaday DJ, Regine WF, Mohiuddin M, Zollinger W, Machtay M, Lee J, et al. Significance of pretreatment hemoglobin level in patients with T1 glottic cancer. Radiat Oncol Invest 1999; 7: 428.
  • 39
    Overgaard J, Hansen HS, Jorgensen K, Hansen MH. Primary radiotherapy of larynx and pharynx carcinoma- an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys 1986; 12(4): 51521.
  • 40
    Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ, et al. Pretreatment hemoglobin level influences local control and survival of T1–T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995, 13(8): 207783.
  • 41
    Stadler P, Becker A, Feldmann HJ, Hansgen G, Dunst J, Wurschmidt F, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999; 44(4); 74954.
  • 42
    San Miguel JF, Sanchez J, Gonzalez M. Prognostic factors and classification in multiple myeloma. Br J Cancer 1989; 59: 1138.
  • 43
    Hannisdal E, Kildahl-Andersen O, Grottum KA, Lamvik J. Prognostic factors in multiple myeloma in a population-based trial. Eur J Haematol 1990; 45: 198202.
  • 44
    Medical Research Council's Working Party on Leukaemia in Adults. Prognostic features in the third MRC myelomatosis trial. Br J Cancer 1980; 42: 83140.
  • 45
    Alexanian R, Balcerzak S, Bonnet JD, Gehan EA, Haut A, Hewlett JS, et al. Prognostic factors in multiple myeloma in a population-based trial. Cancer 1975; 36: 1192201.
  • 46
    Matzner Y, Benbassat J, Polliack A. Prognostic factors in multiple myeloma. Acta Haematol 1978; 60: 25768.
  • 47
    Carbone PP, Kellerhouse LE, Gehan EA. Plasmacytic myeloma. Am J Med 1967; 42: 93748.
  • 48
    Dunphy EP, Petersen LA, Cox RS, Bagshaw MA. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1988; 16: 11738.
  • 49
    Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in Phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 1994; 12(9): 186875.
  • 50
    Mulders PF, Dijkman GA, Fernandez del Moral P, Theeuwes AGM, Debruyne FMJ, and Members of the Dutch Southeastern Urological Cooperative Group. Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. Cancer 1990; 65(12): 275861.
  • 51
    Emrich LJ, Priore RL, Murphy GP, Brady MF, and Investigators of the National Prostatic Cancer Project. Prognostic factors in patients with advanced prostate cancer. Cancer Res 1985; 45: 51739.
  • 52
    Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 1998; 16: 183543.
  • 53
    Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 1995; 13: 294453.
  • 54
    Vigario G, Kurohara SS, George FW. Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer. Radiology 1973; 106: 64952.
  • 55
    Schreiner P, Siracka E, Siracky J, Manka I. The effect of anemia on the radiotherapy results of the uterine cervix cancer. Neoplasma 1975; 22: 65560.
  • 56
    Solberger O, Sorbe B. Fever, haemoglobin and smoking as prognostic factors during the treatment of cervical carcinoma by radiotherapy. Eur J Gynaecol Oncol 1990; 11: 97102.
  • 57
    Thomson JM, Spratt JS Jr. Factors affecting survival in over 500 patients with Stage II carcinoma of the cervix. Radiology 1977; 123: 1813.
  • 58
    French Cooperative Group on Chronic Lymphocytic Leukaemia. Natural history of Stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990; 76: 4557.
  • 59
    Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood 1982; 60: 1298304.
  • 60
    Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, et al. Chronic myelogenous leukemia. Blood 1985; 66: 132635.
  • 61
    Advani SH, Rao DN, Gopal R, Nair CN, Battacharya M. Acute lymphoblastic leukemia end results analysis of treatment and prognostic factors in Indian patients. Am J Hematol 1983; 15: 3543.
  • 62
    Moullet I, Salles G, Ketterer N, Dumontet C, Bouafia F, Neidhart-Berard EM, et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol 1998; 9: 110915.
  • 63
    Fischer RI, Rubbard SM, DeVita VT. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. Blood 1981; 58: 4551.
  • 64
    Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease with alternating potentially non-cross resistant chemotherapy and intermediate dose radiation therapy. J Clin Oncol 1990; 8: 117386.
  • 65
    Citterio G, Bertuzzi A, Tresoldi M, Galli L, Di Lucca G, Scaglietti U, et al. Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol 1997; 31(3): 28691.
  • 66
    Lund B, Williamson P. Prognostic factors for overall survival in patients with advanced ovarian carcinoma. Ann Oncol 1991; 2(4): 2817.
  • 67
    Graf W, Glimelius B, Pahlman L, Bergstrom R. Determinants of prognosis in advanced colorectal cancer. Eur J Cancer 1991; 27(9): 111923.
  • 68
    Edler L, Heim ME, Quintero C, Brummer T, Queisser W. Prognostic factors of advanced colorectal cancer patients. Eur J Cancer Clin Oncol 1986; 22: 12317.
  • 69
    Su CH, Shyr YM, Lui WY, P'eng FK. Factors affecting morbidity, mortality and survival after pancreaticoduodenectomy for carcinoma of the ampulla of Vater. Hepatogastroenterology 1999; 46: 19739.
  • 70
    Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113(3): 72331.
  • 71
    Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17(10): 317381.
  • 72
    Reed WR, Hussey DH, DeGowin RL. Implications of the anaemia of chronic disorders in patients anticipating radiotherapy. Am J Med Sci 1994; 308(1): 915.